This is a working overview of research peptide, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-02-06. Anything still debated is marked as such rather than presented as settled.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic pentadecapeptide | Fifteen amino acids; sequence matches a fragment of a gastric juice protein |
| Molecular formula | C62H98N16O22 | Corresponds to a molecular mass near 1419 Da |
| Primary origin | Fragment of human gastric juice protein BPC | First characterized in the early 1990s |
| Common synonyms | BPC 157; PL 14736; pentadecapeptide BPC 157 | Naming conventions vary across publications |
| Reported stability | Stable in gastric juice during in vitro incubation | Based on laboratory incubation, not clinical data |
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Lyophilized material is generally kept cold, commonly at minus twenty degrees Celsius, and shielded from moisture and light. Solutions are less stable than the dry powder, so repeated freeze-thaw cycles are avoided by splitting the material into single-use portions. Published stability data for this particular peptide are limited, which means suggested hold times should be read as provisional. Long-term refrigeration of reconstituted solutions is not well supported by available evidence.
Identity and purity are checked with standard peptide techniques. Reversed-phase high-performance liquid chromatography separates the main peak from closely related impurities and yields a percentage purity. Mass spectrometry confirms that the measured mass matches the theoretical value. Amino acid analysis offers an independent check on overall composition. These analytical methods characterize the material itself and reveal nothing about how it behaves in a living system.
=== North America === In North America, medical physics training is offered at the master's, doctorate, post-doctorate and/or residency levels. A professional doctorate has also been recently introduced as an option. Several universities in Canada and the United States offer these degrees. As of October 2013, over 70 universities in North America have medical physics graduate programs or residencies that are accredited by The Commission on Accreditation of Medical Physics Education Programs (CAMPEP). The majority of residencies are therapy, but diagnostic and nuclear have also been on the rise in the past several years. In the United States, professional certification is obtained from the American Board of Radiology (for all 4 areas) the American Board of Medical Physics (for MRI), the American Board of Science in Nuclear Medicine (for Nuc Med and PET). As of 2012, enrollment in a CAMPEP-accredited residency or graduate program is required to start the ABR certification process. As of 2013, completion of a CAMPEP-accredited residency is required to advance to part 2 of the ABR certification process. In Canada, professional certification is obtained from the Canadian College of Physicists in Medicine (for all 4 areas and Mammography). Since 2016, eligibility requirements for Radiation Oncology Physics certification includes graduation and post-graduate training from a CAMPEP accredited institution.
DNA-templated synthesis and YoctoReactor technology require the prior conjugation of chemical building blocks (BB) to a DNA oligonucleotide tag before library assembly, therefore more upfront work is required before library assembly. Furthermore, the DNA tagged BBs enable the generation of a genetic code for synthesized compounds and artificial translation of the genetic code is possible: That is the BB's can be recalled by the PCR-amplified genetic code, and the library compounds can be regenerated. This, in turn, enables the principle of Darwinian natural selection and evolution to be applied to small molecule selection in direct analogy to biological display systems; through rounds of selection, amplification and translation.
A gelatine shot (usually called a Jell-O shot in North America and vodka jelly or jelly shot in the UK and Australia) is a shooter in which one or more liquors, usually vodka, rum, tequila, or neutral grain spirit, replaces some of the water or fruit juice that is used to congeal the gel. The American satirist and mathematician Tom Lehrer claims to have invented the gelatine shot in the 1950s while working for the National Security Agency, where he developed vodka gelatine as a way to circumvent a restriction of alcoholic beverages on base. An early published recipe for an alcoholic gelatine drink dates from 1862, found in How to Mix Drinks, or The Bon Vivant's Companion by Jerry Thomas: his recipe for "Punch Jelly" calls for the addition of isinglass or other gelatine to a punch made from cognac, rum, and lemon juice.
== Natural occurrence == Ibogaine occurs naturally in iboga root bark. Ibogaine is also available in a total alkaloid extract of the Tabernanthe iboga plant, which also contains all the other iboga alkaloids and thus has only about half the potency by weight of standardized ibogaine hydrochloride. Due to environmental concerns and low levels in Tabernanthe iboga, ibogaine is often produced via semi-synthesis starting with voacangine, a naturally-occurring alkaloid in Voacanga africana.
Sources: en.wikipedia.org
Kojic acid is an organic compound with the formula HOCH2C5H2O2OH. It is a derivative of 4-pyrone that functions in nature as a chelation agent produced by several species of fungus, especially Aspergillus oryzae, which has the Japanese common name koji. Kojic acid is a by-product in the fermentation process of malting rice, for use in the manufacturing of sake, the Japanese rice wine. It is a mild inhibitor of the formation of pigment in plant and animal tissues, and is used in food and cosmetics to preserve or change colors of substances. It forms a bright red complex with ferric ions.
In the United States alone, sales of the Invega franchise (including Sustenna, Trinza, and Hafyera) reached $3.1 billion in 2024, an 8% increase over the previous year. The market is served primarily by Janssen Pharmaceuticals, with generic competition expected to begin after the key U.S. patent expires on January 26, 2031.
=== Belief === Morea was raised in a Roman Catholic household and has openly celebrated Christian festivals such as Easter with his family. In 2023, Morea was invited among several members of India's Christian community to a Christmas celebration hosted by Prime Minister Narendra Modi at his official residence in New Delhi.
=== X-rays === The discovery of X‑rays by Wilhelm Röntgen in 1895 led to widespread experimentation by scientists, physicians, and inventors. Many people began recounting stories of burns, hair loss and worse in technical journals as early as 1896. In February of that year, Professor Daniel and Dr. Dudley of Vanderbilt University performed an experiment involving X-raying Dudley's head that resulted in his hair loss. A report by Dr. H.D. Hawks, of his suffering severe hand and chest burns in an X-ray demonstration, was the first of many other reports in Electrical Review. Other experimenters, including Elihu Thomson and Nikola Tesla, also reported burns. Thomson deliberately exposed a finger to an X-ray tube over a period of time and suffered pain, swelling, and blistering. Other effects, including ultraviolet rays and ozone, were sometimes blamed for the damage, and many physicians still claimed that there were no effects from X-ray exposure at all. Despite this, there were some early systematic hazard investigations, and as early as 1902 William Herbert Rollins wrote almost despairingly that his warnings about the dangers involved in the careless use of X-rays were not being heeded, neither by industry nor by his colleagues. By this time, Rollins had proved that X-rays could kill experimental animals, could cause a pregnant guinea pig to abort, and that they could kill a foetus. He also stressed that "animals vary in susceptibility to the external action of X-light" and warned that these differences be considered when patients were treated by means of X-rays.
== Accidents == Ethylene oxide is extremely flammable, and its mixtures with air are explosive. When heated it may rapidly expand, causing fire and explosion. Several industrial accidents have been attributed to ethylene oxide explosion. The autoignition temperature is 429 °C (804 °F), decomposition temperature of 571 °C (1,060 °F) at 101.3 kPa (14.69 psi), minimum inflammable content in the air is 2.7%, and maximum limit is 100%. The NFPA 704 rating is Health, 3; Flammability, 4; Instability 2. Ethylene oxide in presence of water can hydrolyze to ethylene glycol and form polyethylene oxide, which then eventually is oxidized by air and leads to hotspots that can trigger explosive decomposition. Fires caused by ethylene oxide are extinguished with conventional media including foam, carbon dioxide, or water. Suppression of this activity can be done by blanketing with an inert gas until total pressure reaches the nonexplosive range. Extinguishing of burning ethylene oxide is complicated by its ability to continue burning in an inert atmosphere and in water solutions. Fire suppression is reached only upon dilution with water above 22:1.
Sources: en.wikipedia.org
PARPs have been shown to affect transcription factor structure and cause recruitment of many transcription factors to form complexes at DNA and elicit transcription. Mono(ADP-ribosyl)transferases are also shown to affect transcription factor binding at promoters. For example, PARP14, a mono (ADP-ribosyl)transferase, has been shown to affect STAT transcription factor binding. Other (ADP-ribosyl)transferases have been shown to modify proteins that bind mRNA, which can cause silencing of that gene transcript.
While P-51s used 110-US-gallon (420 L) drop tanks over Europe, for Japan they frequently used 165-US-gallon (620 L) drop tanks which allowed more loitering time over Japan. While USAAF B-17 and B-24 bombers in Europe were arranged in combat box formations, over Japan the B-29s formed a stream that could stretch up to 200 miles. The escorting P-51s formed three Tar-Cap (Target Combat Air Patrol) squadrons, two squadrons flying on one side of the B-29 stream and the third on the other side, each squadron being 2,000 feet above and 4,000 to 5,000 feet laterally from the bomber stream. Compared to its Japanese adversaries, the P-51 largely outclassed the Imperial Japanese Army Air Service's aging A6M Zero (the most numerous Japanese fighter available), as the A6M's poor high-altitude performance put it at a disadvantage in the P-51's favorable performance envelope. When the P-51 was used for interdiction or strike missions, the A6M was slower but could still out-turn or out climb the P-51 at low to medium altitude. Newer Japanese designs were potent but too few in number. The Kawanishi N1K-J Shiden was fast and agile, but not effective as an interceptor due to a poor rate of climb and reduced engine performance at high altitude. The Imperial Japanese Army Air Service's Nakajima Ki-84 Hayate had performance and an operation ceiling that could match the P-51, however the Ki-84 suffered from manufacturing defects, and its high-maintenance Nakajima Homare engine could not reach its full potential due to lack of ample high-octane fuel.
== Chemistry == Setiptiline has a tetracyclic structure and is a close analogue of mianserin and mirtazapine, with setiptiline being delta(13b,4a),4a-carba-mianserin, and mirtazapine being 6-azamianserin.
=== Surgical irrigation solutions === BSS (ophthalmic irrigation solution) (produced by Alcon) Composition per 1 mL: sodium chloride (NaCl) 6.4 mg, potassium chloride (KCl) 0.75 mg, calcium chloride dihydrate (CaCl2·2H2O) 0.48 mg, magnesium chloride hexahydrate (MgCl2•6H2O) 0.3 mg, sodium acetate trihydrate (C2H3NaO2·3H2O) 3.9 mg, sodium citrate dihydrate (C6H5Na3O7·2H2O) 1.7 mg, sodium hydroxide and/or hydrochloric acid (to adjust pH), and water for injection. The pH is approximately 7.5. The osmolality is approximately 300 mOsm/Kg. BSS Plus (ophthalmic irrigation solution) (produced by Alcon) Composition per 1 mL (once preparation complete): sodium chloride 7.14 mg (122.17 mmol), potassium chloride 0.38 mg (5.097 mmol), calcium chloride dihydrate 0.154 mg (1.04754 mmol), magnesium chloride hexahydrate 0.2 mg (0.983767 mmol), dibasic sodium phosphate 0.42 mg (2.95858 mmol), sodium bicarbonate 2.1 mg (24.998 mmol), dextrose 0.92 mg (5.1067 mmol), glutathione disulfide (oxidized glutathione) 0.184 mg (0.3003 mmol), hydrochloric acid and/or sodium hydroxide (to adjust pH), in water for injection. The reconstituted product has a pH of approximately 7.4. Osmolality is approximately 305 mOsm.
Sources: en.wikipedia.org
It is a synthetic peptide of fifteen amino acids whose sequence matches a fragment of a protein found in human gastric juice. It is studied mainly in laboratory and animal research rather than as an approved medicine.
The letters abbreviate body protection compound, the name given to the parent protein isolated from gastric juice. The number is an identifier attached to the specific fragment, not a dose or a description of a chemical property.
The sequence corresponds to a segment of an endogenous gastric protein, but the isolated fifteen-amino-acid peptide is a synthetic construct. Whether the free fragment circulates in humans at measurable levels is not clearly established in the published literature.
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.